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26 Background Previous studies suggested that patients affected by primary aldosteronism (PA) 
27 have impaired quality of life (QOL) compared to the general population, but a direct 
28 comparison with patients affected by essential hypertension (EH) has never been performed. 
29 The aim of the study was to compare the QOL of patients affected by PA to the QOL of patients 
30 affected by EH. 
31 Material and methods
32 We designed a prospective observational study comparing the QOL of patients with PA and 
33 carefully matched patients with EH before and after treatment. We recruited 70 patients with 
34 PA and 70 patients with EH, matched for age, sex, blood pressure levels and intensity of anti-
35 hypertensive treatment. We assessed QOL at baseline and after specific treatment for PA or 
36 after optimization of medical therapy for patients with EH.
37 Results
38 Patients with PA displayed impaired QOL compared with the general healthy population, but 
39 similar to patients with EH. Both laparoscopic adrenalectomy and treatment with 
40 mineralocorticoid receptor antagonist allowed an improvement of QOL in patients with PA, 
41 that was more pronounced after surgical treatment. Optimization of blood pressure control by 
42 implementation of antihypertensive treatment (without MR antagonists) allowed a minimal 
43 improvement in only one of eight domains in patients with EH. 
44 Conclusions
45 Patients with PA have impaired QOL, which is likely caused by uncontrolled hypertension  
46 and the effects of intensive anti-hypertensive treatment. Surgical and medical treatment of PA 































































47 allows a significant improvement of QOL, by amelioration of blood pressure control and, 













































































62 The World Health Organization considers quality of life (QOL) a key component of “health” 
63 status and recommends to consider the effects of medical treatments by assessing patients’ 
64 well-being with health related QOL evaluation.1 The QOL of patients with primary 
65 aldosteronism (PA) has been neglected until 2010, when a significant reduction of QOL in 
66 patients with aldosterone producing adenoma (APA), compared with the Australian general 
67 population, was reported for the first time.2 In the following years, these findings were 
68 confirmed in larger cohorts of patients with unilateral PA,3–6 and similar findings were obtained 
69 in patients with bilateral or idiopathic hyperaldosteronism (IHA).4,7 
70 Beyond QOL, primary aldosteronism has been associated with anxiety, depressive disorders 
71 and somatization.8–11 Recent findings suggested that aldosterone levels might correlate with 
72 depressive symptoms in women with PA12 and, more broadly, previous studies indicated a 
73 correlation between serum aldosterone levels and the prevalence of depressive disorders in 
74 patients without PA.13,14
75 Well-being is an essential component of QOL and a previous study reported lower 
76 psychological well-being in patients with PA, compared with normotensive control.9 A 
77 following study reported contrasting results, with no differences in well-being of patients with 
78 PA compared to Dutch normative data.11 Several explanations may be offered for the 
79 conflicting results, including the use of different questionnaires, a predominantly male cohort 
80 and the lack of an appropriate control group in one study.
81 PA is the most common cause of endocrine hypertension and affects about 4-6% of patients 
82 with arterial hypertension in the general population.15,16 Beyond the strict criteria for PA, recent 
83 studies identified an autonomous aldosterone secretion in up to 20% of individuals with 
84 hypertension and up to one fifth of patients with normotension.17,18 Specific PA treatments, 
85 both unilateral adrenalectomy and medical treatment with mineralocorticoid receptor (MR) 































































86 antagonists, resulted in significant QOL improvement, that occurred earlier and was more 
87 pronounced in surgically treated patients compared with those medically treated.4,7
88 Some authors proposed that the impaired QOL of patients with PA could be attributed to the 
89 direct effects of aldosterone excess on central nervous system. However, uncontrolled and 
90 resistant hypertension could themselves account for a significant impairment of QOL.19 No 
91 study directly compared the quality of life of patients with PA versus patients with essential 
92 hypertension with similar clinical characteristics.  At the same time, in most of the former 
93 studies, QOL was assessed after PA diagnosis,2,4 making the awareness of the disease a relevant 
94 component in QOL evaluation. Finally, no study compared the effect of specific treatment for 
95 PA versus optimization of medical treatment.
96 In this context, we designed a prospective observational study comparing, for the first time, the 
97 QOL of patients affected by PA (before diagnosis) with patients affected by essential 
98 hypertension (EH), matched for age, sex, blood pressure levels and intensity of drug treatment. 
99 We evaluated the modification of QOL after specific treatment in patients with PA and 
100 compared with QOL modification after optimization of anti-hypertensive therapy in the control 
101 cohort. In order to compare our study with previous findings2-7, we adopted RAND SF-36 as 
102 tool to investigate QOL in our cohort.
103 Materials and methods
104 Study Design
105 The protocol was approved by the ethical committee of the hospital A.O.U. Città della Salute 
106 e della Scienza di Torino and written informed consent was obtained from all recruited patients. 
107 Reporting of the study conforms to broad EQUATOR guidelines.20
108 In the QUALIty of Life of patients with PA in TOrino (QUALITO) study we prospectively 
109 enrolled 140 patients (70 patients with PA and 70 matched controls with EH) from 03/2017 to 
110 09/2019 in Torino, Italy. Patients with PA and EH were matched for sex, age, systolic blood 































































111 pressure (SBP) and intensity of antihypertensive drug treatment (quantified by daily defined 
112 dose, calculated with the online tool available at 
113 https://github.com/ABurrello/PASOPredictor/raw/master/00 - PASO Predictor.xlsm).21
114 All the included patients were affected by arterial hypertension, diagnosed according with the 
115 European Society of Cardiology/European Society of Hypertension (ESC/ESH) guideline 22,23; 
116 diagnosis of EH was made after the exclusion of all the main secondary forms of arterial 
117 hypertension (including hypercortisolism, pheochromocytoma, hyperthyroidism and reno-
118 vascular hypertension), while patients with PA were included following a confirmed diagnosis 
119 according to the Endocrine Society guideline and the recent ESH consensus.24–26 The only 
120 exclusion criterion for EH cohort was treatment with MR antagonists at recruitment or at follow 
121 up. For PA cohort, exclusion criteria were I) patients under MR antagonist or II) previous 
122 adrenalectomy for unilateral PA at recruitment.
123 Diagnosis of primary aldosteronism
124 Before screening test, all interfering antihypertensive drugs were stopped (at least 2 weeks for 
125 ACE-I, ARBs and beta blockers and 4 weeks for diuretics). When complete discontinuation of 
126 antihypertensive treatment was not feasible, non-interfering drugs were administered. The 
127 screening test was considered positive in case of serum aldosterone ≥ 10 ng/dl and aldosterone 
128 to renin ratio (ARR) ≥ 30 ng/dl/ng/ml/h or aldosterone to active renin ratio (AARR) ≥ 2.7 
129 ng/dl/mU/l. Seated saline infusion test (SSIT) or, in case of contraindication, captopril 
130 challenge test (CCT), were used as confirmatory tests. PA was considered confirmed in case 
131 of serum aldosterone post-SSIT ≥ 5 ng/dl or ARR ≥ 30 ng/dl/ng/ml/h after CCT.
132 Subtype diagnosis was performed by computed tomography of the adrenal glands and 
133 unstimulated and/or cosyntropin-stimulated adrenal venous sampling (AVS). A selectivity 
134 index ≥ 3 for unstimulated and ≥ 5 for stimulated AVS was used to define successful 































































135 cannulation of adrenal veins. A lateralization index ≥ 4 or ≥ 3 with contralateral suppression 
136 (contralateral ratio < 1) was used to define unilateral PA. 
137 Quality of life data collection
138 36-Item Short Form Health Survey (RAND SF-36) is a self-administered questionnaire used 
139 to assess health-related QOL and validated in the Italian population.27 RAND SF-36 includes 
140 35 items and 8 different subscales: physical functioning, role limitations due to physical 
141 problems, role limitations due to emotional problems, vitality, general mental health, social 
142 functioning, bodily pain, and general health perceptions.
143 At baseline, RAND SF-36 was self-administered in patients with PA before confirmatory test 
144 and in patients with EH before optimization of antihypertensive medical treatment. 
145 In the PA cohort, RAND SF-36 was also collected 2 and 6 months after laparoscopic surgical 
146 adrenalectomy or initiation of MR antagonist. RAND SF-36 was collected 6 months after 
147 optimization of medical treatment in patients with EH.
148 Data of the PA cohort, at baseline and at 6 months, have been compared to the Italian normative 
149 data from “healthy subjects”.27
150 Statistical methods
151 IBM SPSS Statistics version 26.0 (IBM Corp., Armonk, New York) was used for statistical 
152 analyses. PRISM software (GraphPad, San Diego, CA) was used for charts and graphs 
153 preparation. Data are expressed as mean ± SD for continuous variables with a normal 
154 distribution. Data with non-normal distributions are expressed as median (interquartile range). 
155 Charlson Comorbidy index was used to estimate burden of comorbidity and considered as 
156 categorical variable.28 Statistical significance between groups was calculated in normally 
157 distributed data by paired t test for groups of matched patients and Student t test for independent 
158 samples in other cases. Mann-Whitney U test was used for non-normally distributed data and 
159 Kruskal-Wallis test for paired samples for non-normally distributed data of matched samples. 































































160 Chi-square test was used for qualitative variables. Repeated measure ANOVA was used for 
161 comparison of daily defined dose (DDD) and blood pressure levels during follow up. 
162 Linear mixed model is a statistical approach that can be applied in prospective studies for the 
163 analysis of repeated measures. In contrast to repeated measure ANOVA, usually used for 
164 repeated measures analysis, mixed models consider both fixed and random effects, allowing a 
165 more accurate analysis of prospective data. Moreover, using random effects for baseline values, 
166 mixed models take into account differences in starting point for each subject. 
167 Linear mixed models, with unstructured correlation and maximum likelihood method, were 
168 used for longitudinal comparison of QOL changes and performed with R version 3.6.1. Scores 
169 of the 8 subscales of RAND SF-36 were used as dependent variables. Time, treatment, sex, 
170 diabetes and CCI were considered as fixed factors and potassium, creatinine, age, BMI and 
171 duration of hypertension as covariates. 20 different models were evaluated for each subscale 
172 and minimum Akaike information criterion (AIC) was used for model selection (Supplemental 
173 Methods).
174 Results
175 PA and EH cohort
176 A total of 140 patients were recruited for the QUALITO study in Torino: 70 patients with PA 
177 and 70 patients with EH matched for age, sex, systolic blood pressure and intensity of anti-
178 hypertensive drug treatment (DDD). Of the 70 patients with PA, 43 were diagnosed as affected 
179 by unilateral PA, 37 of whom underwent laparoscopic adrenalectomy (Figure S1). All the 
180 patients that underwent unilateral adrenalectomy displayed complete biochemical outcome at 
181 6 months follow-up according to PASO criteria.29 Twenty out of 70 patients with PA were 
182 classified as IHA and 7 patients with undetermined subtype, because unwilling to undergo AVS 
183 or unsuccessful procedure. Thirty patients were treated with MR antagonist (14 with 
184 spironolactone, 16 with potassium canrenoate), including 6 patients with unilateral PA, 19 































































185 patients with IHA and 5 with undetermined subtype. One of 37 patients after surgical 
186 adrenalectomy and one of 30 patients under MR antagonist were lost at follow up (Figure S1).
187 Principal clinical and biochemical characteristics of patients with EH and PA are summarized 
188 in Table 1. No significant differences were present between the two cohorts for the evaluated 
189 parameters, except for lower serum potassium in PA cohort.
190 Baseline comparison
191 At baseline, patients with PA had non-significant differences in either of the 8 subscales 
192 compared with matched individuals with EH (Figure 1, Table S1). No differences were present 
193 even after stratification for subtype diagnosis, in patients with unilateral PA and IHA (Table 
194 S2-S3), compared with the respective matched patients with EH. 
195 Compared to Italian normative data of “healthy subjects”,27 patients with PA displayed lower 
196 score in 5 of 8 domains: physical functioning, role limitations due to physical health problems, 
197 vitality, social functioning and general health perceptions (Figure 1, Table S1), with similar 
198 results in patients with unilateral PA and IHA, with the exception of social functioning, that 
199 did not differ significantly between patients affected by IHA and healthy subjects (Table S2-
200 S3). At baseline, independently of PA or EH diagnosis, patients with DDD≥3 displayed lower 
201 QOL in two physical subscales than patients with DDD<3 (Tables S4).
202 Follow up
203 After surgical adrenalectomy, patient with APA displayed a significant reduction, at 2 and 6 
204 months of follow up, of SBP (149±13 vs 124±11 vs 121±11 mmHg), diastolic blood pressure 
205 (DBP) (92±9 vs 80±11 vs 78±8 mmHg) and anti-hypertensive treatment (DDD 3.05±1.68 vs 
206 1.31±1.53 vs 0.94±1.26). Patients under MR antagonist showed a reduction of SBP (145±15 
207 vs 134±14 vs 131±13 mmHg) and DBP (88±9 vs 83±9 vs 83±8 mmHg) with a non-significant 
208 increase of anti-hypertensive treatment (DDD 3.07±1.24 vs 3.43±1.42 vs 3.44±1.44). 































































209 Similarly, patients treated with general anti-hypertensive treatment showed SBP and DBP 
210 reduction at 6 months, with increased DDD (Table S5).
211 We used linear mixed models to compare baseline values with follow up scores at 2 and 6 
212 months after treatment, selecting the best of 20 tested models, for each of the 8 subscales 
213 (Supplemental Methods and Table S6). Effect and statistical significance of fixed factors, 
214 covariates and interactions in each of the 8 subscales are showed in Table S7.
215 During follow up, patients undergoing unilateral surgical adrenalectomy displayed a significant 
216 improvement in 4 of 8 domains: physical functioning, vitality, general health perceptions and 
217 general mental health, with the latter significant at 2 but not at 6 months. Patients with PA 
218 treated with MR antagonist, had a significant improvement in 2 domains: physical functioning 
219 and general health perceptions. Patients with EH undergoing optimization of anti-hypertensive 
220 treatment without MR antagonist displayed a significant improvement in only one domain 
221 (general mental health) at 6 months of follow up (Figure 2A-B-C, Table S8). 
222 Six months comparison
223 At 6 months, adrenalectomized patients displayed higher scores in physical activity and general 
224 health perceptions, compared to patients under general anti-hypertensive treatment, and higher 
225 score in social functioning, compared to patients under MR antagonist. Patients with PA under 
226 MR antagonist had higher score of physical functioning compared to patients under general 
227 anti-hypertensive treatment (Figure 2D, Table S9).
228 Six months after surgery, adrenalectomized patients displayed similar score in 7 of 8 domains, 
229 compared to Italian normative data of healthy subjects,27 with lower score in only general 
230 health perception. Instead, after 6 months of medical treatment, patients with MR antagonist 
231 had lower scores in 4 of 8 domains compared to healthy subjects (Figure 3, Table S10).
232 Discussion































































233 QOL is a well-recognized component of health and QOL assessment has an important role in 
234 the evaluation of the impact of diseases on affected patients. Whether the impaired QOL of 
235 patients affected by PA is the result of aldosterone effect on the central nervous system or the 
236 consequence of uncontrolled blood pressure is still an open question.30
237 In the QUALITO study we compared, for the first time, the QOL of patients affected by PA to 
238 the QOL of carefully matched patients affected by EH, as control group. The scores of patients 
239 affected by PA were lower than healthy subjects, but not different from those of patients 
240 affected by EH, suggesting that the impairment of QOL in PA could be attributable to 
241 uncontrolled blood pressure and anti-hypertensive treatment, more than a direct effect of 
242 aldosterone excess.
243 Female sex, obesity and metabolic syndrome have been related to reduced QOL in previous 
244 studies.3,31 Supporting these findings, in our study, sex female had a significant negative impact 
245 on 6 of 8 domains, including both physical and emotional subscales; similarly,  high BMI had 
246 a significant negative impact in role limitations due to physical health problems and general 
247 health perception. Considering the known relationship between primary aldosteronism, obesity 
248 and metabolic syndrome, it is possible that the coexistence of these conditions may 
249 synergistically contribute to the reduction of QOL in patients with PA.32
250 In agreement with previous studies,2–4,7 we observed that both surgical and medical treatments 
251 for PA induced a significant improvement in QOL, that was remarkably more pronounced in 
252 the surgery group compared with the MR antagonist group. The optimization of anti-
253 hypertensive treatment, without MR blockade, in patients affected by EH, resulted into a 
254 minimal increase in only one of 8 domains of QOL. This result suggests that reduction of blood 
255 pressure levels per se, is probably not sufficient for a significant improvement of QOL and that 
256 a specific role for MR antagonists, beyond its anti-mineralocorticoid activity, can be 
257 hypothesized.































































258 Multiple factors are likely working synergistically, reducing QOL in patients with hypertension 
259 and PA, including disease awareness, medical treatment and uncontrolled blood pressure. 
260 Knowledge of the disease is a key component of impaired QOL in many conditions. Patients 
261 aware of the diagnosis of arterial hypertension have lower QOL than patients unaware of the 
262 disease, independently of blood pressure levels.33 Therefore, patients’ perception of PA-related 
263 cardiovascular risk, the need of invasive procedure for subtype diagnosis (such as adrenal 
264 venous sampling) and lifestyle recommendations (such as dietary modification) can further 
265 impact their QOL. In our study, the questionnaire was administered before PA diagnosis, thus 
266 eliminating the potential bias of disease-awareness. 
267 Another important factor affecting the QOL is represented by anti-hypertensive treatment. In a 
268 previous study, the QOL in physical and mental components was higher in patients taking < 4 
269 anti-hypertensive medications than in patients taking a higher number of drugs. The association 
270 between number of drugs and mental component was significant even after correction for the 
271 main confounding factors including blood pressure levels.34 We confirmed this finding, 
272 reporting lower QOL in patients with DDD≥3 than patients with DDD<3 at baseline evaluation, 
273 independently from the final diagnosis (PA or EH).
274 In our study, patients treated with MR antagonist or optimization of anti-hypertensive treatment 
275 achieved blood pressure control by increase of drug treatment. On the counterpart, six months 
276 after surgery, the mean DDD dropped to less than 1 in patients adrenalectomized. This 
277 difference probably contributes to the significant improvement in QOL observed in patients 
278 undergoing surgical treatment for unilateral PA, allowing a normalization of QOL scores in 7 
279 of 8 domains, compared to healthy subjects.
280 Among patients with hypertension under anti-hypertensive treatment, the highest QOL in 
281 physical component is encountered in those with SBP around 125 mmHg and DBP around 75 
282 mmHg.34 After surgery, adrenalectomized patients displayed lower blood pressure levels than 































































283 patients under MR antagonist or general anti-hypertensive treatment, with values close to the 
284 figures reported above. Therefore, beyond reduction of anti-hypertensive treatment, the 
285 achievement of lowest blood pressure could probably contribute to the better quality of life in 
286 adrenalectomized patients.
287 The importance of psychosocial stress in arterial hypertension has been largely evaluated in 
288 the last decade. A recent study expanded this concept, introducing and highlighting the 
289 importance of allostatic load in arterial hypertension.35 Allostatic load is the reflection of 
290 cumulative effects of daily life experiences, including ordinary and extra-ordinary events.36 
291 Allostatic load is significantly more prevalent in patients with arterial hypertension than 
292 individuals with normotension and patients with hypertension and allostatic load display 
293 significantly decreased quality of life.35 The role of allostatic load in PA has never been 
294 evaluated. This aspect should probably be investigated in future studies to better elucidate the 
295 development of impaired QOL in PA. 
296 Patients with PA treated with MR antagonist displayed a significant increase in the score 
297 related to physical functioning and general health perceptions. In particular, the physical 
298 functioning score was significantly higher after 6 months, compared to patients with EH treated 
299 with medical treatment, without MR blockade. This finding may suggest a direct role of MR 
300 antagonist in the improvement of physical functioning, beyond blood pressure control per se. 
301 High aldosterone levels have been associated with significantly lower exercise capacity in 
302 patients with chronic heart failure,37 and spironolactone significantly improved exercise 
303 tolerance.38 Spironolactone may act by reduction of myocyte apoptosis and enhancing of 
304 skeletal muscle contractility.39
305 The limits of our study are the absence of a control group of patients with PA treated with 
306 optimization of medical treatment without MR blockade, the absence of a control group of 
307 patients with EH treated with MR antagonist, the absence of a control group of normotensive 































































308 subjects collected in the same setting and the lack of anxiety and depression symptoms 
309 evaluation. The strengths and novelties of this study are the comparison of QOL of patients 
310 with PA with matched patients with EH, the comparison of specific treatments for PA 
311 (adrenalectomy and MR antagonist) versus optimization of medical treatment in a similar 
312 group of patients, the diagnosis and subtype diagnosis of PA according to guidelines, and the 
313 administration of the first questionnaire for QOL assessment before PA diagnosis.
314 In conclusion, patients with PA displayed lower QOL than healthy subjects, but not different 
315 from matched patients with EH. Treating patients affected by APA with surgical adrenalectomy 
316 allows a better control of blood pressure levels, with lower anti-hypertensive treatments, 
317 reaching a significantly higher QOL at medium term follow up than medical therapy alone. 
318 Treatment with MR antagonist allows a significant improvement in physical aspects of QOL 
319 compared to optimization of medical therapy without MR blockade. 
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442 Figure 1. Baseline QOL: PA vs. EH-matched controls and healthy subjects. Comparisons were 
443 performed by paired t-test for PA vs. EH and unpaired t-test for PA vs. healthy subjects.
444 QOL=quality of life, PA=primary aldosteronism, EH=essential hypertension, PF=physical 
445 functioning, RLP=role limitations due to physical problems, RLE=role limitations due to 































































446 emotional problems, V=vitality, GMH=general mental health, SF=social functioning, 
447 BP=bodily pain, GHP=general health perceptions. * = significant at p<0.05 PA vs. healthy 
448 subjects. 
449
450 Figure 2. Longitudinal comparison of QOL and cross-sectional comparison at 6 months in 
451 patients with different treatments. Comparisons are considered significant at at p<0.05. Figure 
452 2A-2B-2C: * = 6 months vs. Time 0, † = 2 months vs. Time 0. Figure 2D: * = adrenalectomy 
453 vs. general anti-HT treatment, † = MR antagonist vs. general anti-HT treatment, ‡ = 
454 adrenalectomy vs. MR antagonist. Estimated mean scores comparison have been performed by 
455 linear mixed models (details in Supplemental Methods).
456
457 PF=physical functioning, RLP=role limitations due to physical problems, RLE=role limitations 
458 due to emotional problems, V=vitality, GMH=general mental health, SF=social functioning, 
459 BP=bodily pain, GHP=general health perceptions, MR=mineralocorticoid receptor, anti-
460 HT=anti-hypertensive. 
461
462 Figure 3. Six months QOL: patients treated with ADX and MRA vs. healthy subjects. * = 
463 significant at p<0.05 adrenalectomy vs. healthy subjects, † = MR antagonist vs. healthy 
464 subjects. Comparisons were performed by unpaired t-test.
465 PF=physical functioning, RLP=role limitations due to physical problems, RLE=role limitations 
466 due to emotional problems, V=vitality, GMH=general mental health, SF=social functioning, 


















































































SBP (mmHg) 146±14 143±13 0.118
DBP (mmHg) 90±10 90±9 0.806
DDD 3.02±1.46 2.83±1.35 0.427
Duration of hypertension (years) 5 (1-10) 7 (1-16) 0.233
Creatinine (mg/dl) 0.87±0.21 0.91±0.19 0.385
Sodium (mmol/l) 141±2 142±2 0.103
Potassium (mmol/l) 3.6±0.5 4.1±0.4 <0.001
BMI (kg/m2) 25.9±4.1 26.9±5.4 0.196











Presence of comorbidity by CCI 9 (12.8) 20 (28.6) 0.152
472 PA=primary aldosteronism, EH=essential hypertension, SBP=systolic blood pressure, DBP=diastolic 
473 blood pressure, DDD=daily defined dose, BMI=body mass index, IFG=impaired fasting glucose, 
474 CCI=Charlson Comorbidity Index. Comparisons were performed by unpaired t-test for continuous 
475 variables and χ2 test for categorical variables. 
476































































Figure 1. Baseline QOL: PA vs. EH-matched controls and healthy subjects. 
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Figure 2. Longitudinal comparison of QOL and cross-sectional comparison at 6 months in patients with 
different treatments. 
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